{"nctId":"NCT00412893","briefTitle":"Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis","startDateStruct":{"date":"2007-03-07","type":"ACTUAL"},"conditions":["Aspergillosis","Invasive Fungal Infection"],"count":527,"armGroups":[{"label":"Isavuconazole","type":"EXPERIMENTAL","interventionNames":["Drug: Isavuconazole"]},{"label":"Voriconazole","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Voriconazole"]}],"interventions":[{"name":"Isavuconazole","otherNames":["ASP9766","BAL8557"]},{"name":"Voriconazole","otherNames":["VFend"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients must have proven, probable or possible invasive fungal disease caused by Aspergillus species or other filamentous fungi\n* Female patients must be non-lactating and at no risk for pregnancy\n\nExclusion Criteria:\n\n* Patients with invasive fungal infections other than Aspergillus species or other filamentous fungi\n* Evidence of hepatic dysfunction at Baseline or moderate to severe renal dysfunction\n* Patients with chronic aspergillosis, or aspergilloma or allergic bronchopulmonary aspergillosis\n* Patients who have received more than 4 days of systemic antifungal therapy other than fluconazole within the 7 days prior to the first administration of study medication\n* Patients previously enrolled in a Phase III study with isavuconazole\n* Patients with a body weight \\</= 40 kg","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"All-cause Mortality Through Day 42","description":"All-cause mortality is represented as the percentage of participants who died after first dose of study drug through Day 42 from any cause. Participants with unknown survival status through Day 42 were included as deaths in the calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"20.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Overall Outcome of Success Evaluated by the Data Review Committee (DRC)","description":"The DRC was an independent, blinded committee consisting of experts in the field of infectious disease who assessed patients' outcomes. The overall response was based on the DRC-assessed clinical, mycological and radiological responses. Success was defined as the resolution or partial resolution of all attributable clinical symptoms and physical findings, the eradication or presumed eradication of the original causative organism cultured or identified by histology/cytology at Baseline and a \\> 50% improvement in radiological response from Baseline (or improvement of at least 25% from Baseline for the Day 42 analysis or End of Treatment if it occurred prior to Day 42). End of treatment (EOT) is the last day of study drug administration. For the Day 42 and Day 84 analyses, any visits that the DRC assessed as Not Done were considered a failure for that visit. A death before Day 42 was also considered a failure, even if the DRC assessed the participant to be a success prior to death.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"35.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.2","spread":null},{"groupId":"OG001","value":"32.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":null},{"groupId":"OG001","value":"36.4","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality Through Day 84","description":"All-cause mortality is represented as the percentage of participants who died after first dose of study drug through Day 84 from any cause. Participants with unknown survival status through Day 84 were included as deaths in the calculation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":null},{"groupId":"OG001","value":"31.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With an Overall Outcome of Success Evaluated by Investigator","description":"Overall response based on investigators' assessments was not derived as it was not deemed necessary because participants overall response status was determined by the DRC. All investigators' assessments of clinical, mycological and radiological responses are analyzed separately (see Outcome Measures 8-10).","classes":[]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Response Assessed by the DRC","description":"Blinded assessments of clinical symptoms and physical findings of invasive fungal disease were performed by the independent DRC. Clinical response is defined as the resolution or partial resolution of all attributable clinical symptoms and physical findings. Failure is defined as no resolution of any attributable clinical symptoms and physical findings and/or worsening. Participants with no attributable signs and symptoms present at Baseline and no symptoms attributable to invasive fungal disease (IFD) developed post-baseline were classified as \"Not Applicable.\" End of treatment is the last day of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"57.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.1","spread":null},{"groupId":"OG001","value":"44.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"60.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Mycological Response Assessed by the DRC","description":"Blinded mycological assessments of the participant's invasive fungal disease status were performed by the independent DRC using the results from fungal culture and isolation and/or histology/cytology of biopsy or biological fluid samples from the infected site. Mycological response is defined as eradication or presumed eradication of the original causative organism cultured or identified by histology/cytology at Baseline. Failure was defined as persistence or presumed persistence. Participants with no mycological evidence available at Baseline were classified as \"Not Applicable\". End of treatment is the last day of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.9","spread":null},{"groupId":"OG001","value":"39.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.0","spread":null},{"groupId":"OG001","value":"36.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.8","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Radiological Response Assessed by the DRC","description":"Independent reviews of radiology assessments were completed by radiology experts which were provided to the independent, blinded DRC. Blinded radiological assessments were performed by the DRC. Radiological response is defined as a â‰¥ 50% improvement from Baseline, or improvement of at least 25% from Baseline for the Day 42 analysis or if end of treatment occurred before Day 42. Participants without any radiology at Baseline were considered \"Not Applicable.\" End of Treatment is the last day of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"34.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.0","spread":null},{"groupId":"OG001","value":"29.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.1","spread":null},{"groupId":"OG001","value":"33.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Clinical Response Assessed by the Investigator","description":"Assessment of clinical symptoms and physical findings of invasive fungal disease were performed by the investigator. Clinical response is defined as the resolution or partial resolution of all attributable clinical symptoms and physical findings. Failure is defined as no resolution of any attributable clinical symptoms and physical findings and/or worsening, or if results were unavailable or the participant was unevaluable. Participants with no attributable signs and symptoms present at Baseline were classified as \"Not Applicable.\" End of treatment is the last day of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.2","spread":null},{"groupId":"OG001","value":"61.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.4","spread":null},{"groupId":"OG001","value":"44.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"64.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Mycological Response Assessed by the Investigator","description":"Mycological assessments of the participant's invasive fungal disease status were performed by the investigator using the results from fungal culture and isolation and/or histology/cytology of biopsy or biological fluid samples from the infected site. Mycological response is defined as eradication or presumed eradication of the original causative organism cultured or identified by histology/cytology at Baseline. Failure was defined as persistence or presumed persistence. Participants with no mycological evidence available at Baseline, or no mycological follow-up results available or indeterminate results were classified as \"Not Applicable\". End of treatment is the last day of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.3","spread":null},{"groupId":"OG001","value":"50.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.7","spread":null},{"groupId":"OG001","value":"37.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null},{"groupId":"OG001","value":"55.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With a Radiological Response Assessed by the Investigator","description":"Radiological assessments were performed by the investigator. Radiological response is defined as a â‰¥ 50% improvement from Baseline, or improvement of at least 25% from Baseline for the Day 42 analysis or if end of treatment occurred before Day 42. Failure is defined as a \\< 25% improvement at any time or results not available. Participants with no signs on radiological images at Baseline were considered \"Not Applicable.\" End of Treatment is the last day of study drug administration.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.1","spread":null},{"groupId":"OG001","value":"51.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.3","spread":null},{"groupId":"OG001","value":"41.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","spread":null},{"groupId":"OG001","value":"47.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events, Reported by System Organ Class","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":null},{"groupId":"OG001","value":"255","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"174","spread":null},{"groupId":"OG001","value":"180","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"158","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"148","spread":null},{"groupId":"OG001","value":"144","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"121","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"110","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"70","spread":null},{"groupId":"OG001","value":"86","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":134,"n":257},"commonTop":["Nausea","Vomiting","Pyrexia","Diarrhoea","Hypokalaemia"]}}}